Trade Names: | |
Synonyms: | |
Status: | Approved (1981) |
Entry Type: | Small molecule |
Molecule Category: | UNKNOWN |
ATC: | L01DC03 |
UNII: | 50SG953SK6 |
InChI Key | NWIBSHFKIJFRCO-WUDYKRTCSA-N |
---|---|
Smile | |
InChI |
|
Property Name | Value |
---|---|
Molecular Formula | C15H18N4O5 |
Molecular Weight | 334.33 |
AlogP | -1.65 |
Hydrogen Bond Acceptor | 8.0 |
Hydrogen Bond Donor | 3.0 |
Number of Rotational Bond | 3.0 |
Polar Surface Area | 146.89 |
Molecular species | NEUTRAL |
Aromatic Rings | 0.0 |
Heavy Atoms | 24.0 |
Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
---|---|---|---|---|---|---|
Enzyme
Hydrolase
|
- | - | - | - | 3 | |
Enzyme
Oxidoreductase
|
- | - | - | 25000 | - |
Mesh Heading | Maximum Phase | Mesh ID | Reference |
---|---|---|---|
Glaucoma | 4 | D005901 | ClinicalTrials |
Carcinoma, Hepatocellular | 3 | D006528 | ClinicalTrials |
Anus Neoplasms | 3 | D001005 | ClinicalTrials |
Uterine Cervical Neoplasms | 3 | D002583 | ClinicalTrials |
Mesothelioma | 3 | D008654 | ClinicalTrials |
Anus Neoplasms | 3 | D001005 | ClinicalTrials |
Carcinoma in Situ | 3 | D002278 | ClinicalTrials |
Urinary Bladder Neoplasms | 3 | D001749 | ClinicalTrials |
Pancreatic Neoplasms | 3 | D010190 | ClinicalTrials |
Carcinoma, Non-Small-Cell Lung | 3 | D002289 | ClinicalTrials |
Anus Neoplasms | 3 | D001005 | ClinicalTrials |
Nasopharyngeal Neoplasms | 3 | D009303 | ClinicalTrials |
Urinary Bladder Neoplasms | 3 | D001749 | ClinicalTrials |
Carcinoma, Transitional Cell | 3 | D002295 | ClinicalTrials |
Carcinoma | 3 | D002277 | ClinicalTrials |
Colorectal Neoplasms | 3 | D015179 | ClinicalTrials |
Lung Neoplasms | 3 | D008175 | ClinicalTrials |
Urinary Bladder Neoplasms | 3 | D001749 | ClinicalTrials |
Lung Neoplasms | 3 | D008175 | ClinicalTrials |
Head and Neck Neoplasms | 3 | D006258 | ClinicalTrials |
Breast Neoplasms | 3 | D001943 | ClinicalTrials |
Stomach Neoplasms | 3 | D013274 | ClinicalTrials |
Urinary Bladder Neoplasms | 3 | D001749 | ClinicalTrials |
Esophageal Stenosis | 2 | D004940 | ClinicalTrials |
Pterygium | 2 | D011625 | ClinicalTrials |
Cholangitis, Sclerosing | 2 | D015209 | ClinicalTrials |
Carcinoma, Squamous Cell | 2 | D002294 | ClinicalTrials |
Sarcoma | 2 | D012509 | ClinicalTrials |
Glaucoma, Open-Angle | 2 | D005902 | ClinicalTrials |
Cholangiocarcinoma | 2 | D018281 | ClinicalTrials |
Glaucoma, Neovascular | 2 | D015355 | ClinicalTrials |
Corneal Opacity | 2 | D003318 | ClinicalTrials |
Appendiceal Neoplasms | 2 | D001063 | ClinicalTrials |
Liver Neoplasms | 2 | D008113 | ClinicalTrials |
Biliary Tract Neoplasms | 2 | D001661 | ClinicalTrials |
Keratoconus | 2 | D007640 | ClinicalTrials |
Neoplasm Metastasis | 1 | D009362 | ClinicalTrials |
Renal Insufficiency, Chronic | 1 | D051436 | ClinicalTrials |
Myopia | 1 | D009216 | ClinicalTrials |
Leukemia | 1 | D007938 | ClinicalTrials |
Urethral Stricture | 1 | D014525 | ClinicalTrials |
Side effects | Relative Frequency (%) | Labels | |
---|---|---|---|
Cardiac disorders Pulmonary oedema | 65.0 |
Resources | Reference |
---|---|
CAS NUMBER | 50-07-7 |
ChEBI | 27504 |
ChEMBL | CHEMBL105 |
DrugBank | DB00305 |
DrugCentral | 1819 |
EPA CompTox | DTXSID2020898 |
FDA SRS | 50SG953SK6 |
Human Metabolome Database | HMDB0014450 |
Guide to Pharmacology | 7089 |
KEGG | C06681 |
PharmGKB | PA450524 |
PubChem | 5746 |
SureChEMBL | SCHEMBL3760 |
ZINC | ZINC000030726187 |